Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP)

Verition Fund Management LLC lessened its stake in Immutep Limited (NASDAQ:IMMP) by 25.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,000 shares of the biotechnology company’s stock after selling 9,000 shares during the quarter. Verition Fund Management LLC’s holdings in Immutep were worth $57,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Meridian Wealth Management LLC grew its position in Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 17,250 shares during the last quarter. XY Capital Ltd increased its position in Immutep by 108.3% during the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock worth $239,000 after purchasing an additional 56,344 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Immutep during the 2nd quarter worth approximately $26,000. Institutional investors own 2.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their price target on shares of Immutep from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, November 15th.

Immutep Price Performance

NASDAQ:IMMP opened at $2.13 on Wednesday. The stock’s 50-day moving average is $1.99 and its 200-day moving average is $2.18. Immutep Limited has a 1-year low of $1.66 and a 1-year high of $3.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25.

Immutep Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.